The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small lung cancer or renal cell carcinoma. These humanized monoclonal antibodies target inhibitory receptors (e.g. CTLA-4, PD-1, LA...

Full description

Bibliographic Details
Main Authors: Rossana Franzin, Giuseppe Stefano Netti, Federica Spadaccino, Camillo Porta, Loreto Gesualdo, Giovanni Stallone, Giuseppe Castellano, Elena Ranieri
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitors
AKI (acute kidney injury)
mTOR inhibitor
CTLA-4
PD-1-PDL-1 axis
immunosenescence and inflammaging
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.574271/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.574271/full

Similar Items